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recognized with several different IV Ig products.5–10 Re-
See editorial on page 1307. cent molecular analysis has confirmed hepatitis C virus
(HCV) as the cause of these outbreaks.11,12 The develop-
Background & Aims: Hepatitis C virus (HCV) infection ment of efficient antibody tests for hepatitis C has now
has been associated with intravenous (IV) immunoglob- enabled the statutory introduction of screening and ex-
ulin (Ig), and plasma donations used to prepare IV Ig clusion of anti-HCV antibody–positive plasma donors,
are now screened to prevent transmission. Thirty-six although the acceptance of screening was controversial.13
patients from the United Kingdom received infusions
There was concern that transmission of hepatitis C wasfrom a batch of anti-HCV antibody–screened intrave-
still possible if plasma was donated by acutely infectednous Ig (Gammagard; Baxter Healthcare Ltd., Thetford,
individuals who had not yet seroconverted.14,15 Transmis-Norfolk, England) that was associated with reports of
sion could then occur if complete viral inactivation oracute hepatitis C outbreak in Europe. The aim of this
removal did not take place during the manufacturingstudy was to document the epidemiology of this out-
process. Therefore, although IV Ig preparations werebreak. Methods: Forty-six patients from the United
Kingdom treated with Gammagard (34 exposed and thought to be safe and unlikely to transmit HCV infec-
12 unexposed to the batch) returned epidemiological tion, routine monitoring of liver function test results was
questionnaires. Results: Eighty-two percent of the ex- recommended for all patients undergoing such therapy.16
posed patients (28 of 34) became positive for HCV Early in 1994, abnormal liver function test results
RNA. Eighteen percent of the patients (6 of 34) who were detected on routine testing among patients in the
had infusions with this batch tested negative for HCV United Kingdom undergoing IV Ig therapy using the
RNA, but 2 of the patients had abnormal liver function
brand Gammagard (Baxter Healthcare Ltd., Thetford,and subsequently seroconverted to anti-HCV antibody
Norfolk, England). At the same time, several cases ofpositive. Twenty-seven percent of the patients (9 of 34)
suspected acute hepatitis C infection were reported afterdeveloped jaundice, and 79% (27 of 34) had abnormal
the use of the same product in Sweden and Spain. Inliver transferase levels. Virus isolates (n Å 21), includ-
response, Gammagard was withdrawn worldwide on Feb-ing an isolate from the implicated batch, were genotype
ruary 21, 1994. It became rapidly clear that in the United1a and virtually identical by sequence analysis of the
NS5 region, consistent with transmission from a single Kingdom and Spain, all patients developing possible
source. Conclusions: Hepatitis C infection can be trans- HCV infection had been treated recently with one batch
mitted by anti-HCV–screened IV Ig. Careful documenta- of the product. This enabled identification of all exposed
tion of IV Ig batch numbers and regular biochemical patients. Other cases subsequently reported in the United
monitoring is recommended for all IV Ig recipients. States and in Sweden were associated with different con-
taminated batches of the product, and because several
batches were implicated, identification and subsequentI follow-up was more difficult.17 In this study, we reportntravenous (IV) immunoglobulin (Ig) is an establishedtherapy for immune deficiency. It is used in the man-
agement of primary1 and secondary immune deficiency2,3
Abbreviations used in this paper: CVID, common variable immuno-and as an immunomodulatory agent in many autoim-
deficiency; RT-PCR, reverse-transcription polymerase chain reaction.
mune diseases.4 As IV Ig therapy developed through  1996 by the American Gastroenterological Association
0016-5085/96/$3.00the 1980s, outbreaks of non-A, non-B hepatitis were
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NS-5 sequence recovered from the implicated batch of Gam-the initial follow-up of the exposed patients in the United
magard.Kingdom.
Results
Patients and Methods
Patient Details
In late February 1994, abnormal liver function was
Forty-six questionnaires were returned from 48detected in several patients in the United Kingdom who were
identified patients who received Gammagard at the 19receiving Gammagard. All of these patients had been treated
with one particular batch (93F21AB11B) within the preceding local centers, regardless of the batch numbers within the
7 weeks (from December 20, 1993, to February 18, 1994). last 14 months (from January 1993 to the withdrawal
This batch was also associated with cases of acute hepatitis C of Gammagard by Baxter Healthcare). Patient details are
in Spain. Data were obtained from the manufacturer detailing summarized in Table 1. No questionnaire was returned
all centers in the United Kingdom supplied with Gammagard from the 2 remaining patients: a Greek child who re-
since 1991. Details of the batch numbers and the recall of all ceived IV Ig while in intensive care before returning to
remaining stocks of Gammagard were used to identify and Greece, and a woman with preexisting liver cirrhosis
contact the centers where the implicated batch had been used.
(HCV-related postblood products) who has since received
Thirty-six patients who had received injections from this batch
a liver transplant. None of the 46 patients had a historyfrom 19 local centers (care supervised from 9 regional immu-
of illicit intravenous drug use (street drugs), tattoos, ornology centers) were identified within the United Kingdom.
sexual contact with individuals with hepatitis. One pa-We also identified 12 patients who underwent Gammagard
tient who received injections from the implicated batchtherapy at these centers during the same period but who did
had a 2-year history of lichen planus (a condition sug-not receive injections from this batch or any Gammagard lots
gested to be associated with HCV infection), but nonereleased after 93F21AB11B. Their physicians were initially
contacted by telephone and then invited to return a follow- of the rest had any history or evidence of other HCV-
up questionnaire. The questionnaire included center details, related disorders such as membranous glomerulonephri-
individual patient details (indication and history of IV Ig ther- tis, cryoglobulinemia, or porphyria cutanea tarda. Two
apy, history of previous liver disease, details of current episode, of the patients had worked within the health care field
and risk factors for HCV), and laboratory results. Any available (one as a dentist and the other as a nurse).
laboratory data for the year before exposure were collected for
each case. Abnormal liver function test results were defined as Association With Batch Numbers of
two times greater than baseline value for each individual. Data Gammagard and HCV Infection
were analyzed using the World Health Organization epidemi-
To establish which batch was associated with theology program EPI-INFO (version 5).
transmission of HCV in these cases in the United King-To confirm infection, clotted blood samples were obtained,
dom, details of all batches of Gammagard received sinceand the serum was removed and frozen within 6 hours of
January 1993 were available for 27 of 46 patients (14venesection. HCV RNA was detected by reverse-transcription
HCV RNA–positive and 13 HCV RNA-negative). Uni-polymerase chain reaction (RT-PCR). Sera stored (020C) be-
variate analysis was performed on each batch (n Å 17)fore exposure were available for 21 of 36 patients and were
compared with HCV RNA detection (data not shown).also tested for HCV RNA. Because RNA degrades easily, sera
stored at the same time from a known case of long-standing Only 1 of 17 batches (93F21AB11B) was positively asso-
HCV infection were used as positive control for 19 of 21 cases. ciated with transmission of HCV (x2 test, 17.1; P õ
To establish whether infection was caused by the same virus, 0.00003, Fisher’s Exact Test). In all patients who re-
the genotype and subtype of representative samples from sev- turned the questionnaire (n Å 46), the relative risk for
eral centers were ascertained. Analysis was performed on a being HCV RNA positive and having used the batch
segment (222 base pairs; positions 7975–8196) of the NS-5 93F21AB11B was 9.88 (Greenland–Robbins 95% con-
gene, which was amplified, sequenced, and analyzed as pre- fidence limits, 1.50 õ relative risk õ 64.92; P Å
viously described.18 Phylogenetic relationships were investi-
0.0001) with an odds ratio of 51.33 (Cornfield 95%
gated between nucleotide sequences amplified from patients
confidence limits, 4.84 õ odds ratio õ 1315).exposed to the implicated batch of Gammagard and epidemio-
logically unrelated type 1a variants from the United States HCV PCR
and Europe (including United Kingdom, Ireland, and Europe)
Twenty-eight of 34 patients (82.4%) treated with(Figure 1). Sequence distances were calculated using DNAML
the batch (93F21AB11B) became HCV-positive as de-program (in PHYLIP inference package, version 3.5, Univer-
tected by PCR within 4 months of exposure. The re-sity of Washington, Seattle, WA) in a dataset containing
maining 6 exposed patients who have had documentedHCV-J (type 1b) as an outgroup. Control sequences were ob-
tained from published sources. The analysis also included an infusions with batch 93F21AB11B have tested negative
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Figure 1. Phylogenetic tree of HCV isolates from recipients compared with controls based on sequence analysis of the NS-5 region (see
Patients and Methods). Controls were labeled by isolate and country of origin and recipients of Gammagard by isolate only.
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Table 1. Patient Details viral isolates has shown no significant nucleotide varia-
tion between virus isolates from separate cases or theBatch 93F21AB11
sequence amplified from batch 93F21AB11B (Figure 1).
Clinical features Exposed Not exposed Total This is consistent with transmission from this batch and
No. of patients 34 12 46 contamination from a single donor.
Age (yr, mean [range]) 42.8 (6–77) 37.8 (23–52) 41.5
Male/female 15/19 7/5 22/24 HCV SerologyIndication for IV Ig therapy
CVID 18 10 28 Only 22 of the 34 (65%) exposed patients hadIg subclass deficiency 8 1 9
Chronic lymphocytic leukemia 3 3 been tested for anti-HCV antibody by second-generation
Myeloma 2 2 enzyme-linked immunosorbent assay. Three were posi-
X-linked gammaglobulinemia 1 1
tive (2 CVID and 1 Ig subclass deficiency) on initialDrug-induced 1 1
hypogammaglobulinemia testing 1–3 months after exposure. Seventeen of the pa-
Hypogammaglobulinemia due 1 1
tients who initially tested negative have been tested ato intestinal
lymphangiectasia second time and 6 patients had seroconverted (3 CVIDs,
X-linked hyper IgM syndrome 1 1
1 Ig subclass deficiency, and 2 myelomas).
Clinical Features
Nine of the 34 exposed patients (27%) developedfor HCV using PCR; 4 patients were tested on at least
three occasions up to 4 months after exposure, and the jaundice (bilirubin level, ú50 IU/L), and 27 of the 34
(79.4%) had abnormal liver transferase levels (aspartateother 2 have been tested twice. Two of the HCV RNA–
negative patients had abnormal liver function test results aminotransferase or alanine aminotransferase) within 4
months after the first exposure to the contaminatedand have seroconverted for anti-HCV. The first patient
had myeloma and recommenced IV Ig therapy with an- batch. In all patients with abnormal liver transaminase
levels, abnormal values were found on more than oneother anti-HCV–screened product. The other had Ig de-
ficiency and Crohn’s disease and developed abnormal liver occasion. The mean time from individual exposure to
batch 93F21AB11B to the first documented abnormalfunction after exposure (documented by his primary care
physician); however, when finally tested for HCV mark- liver transaminase level was 44.59 days (range, 4–119
days; n Å 22; with 60% of values abnormal on theers (101 days after exposure), he had seroconverted for
anti-HCV antibody but RNA was negative. In HCV- first available testing after exposure). Eighteen of the 34
patients who received the contaminated batch (52.9%)positive cases by PCR, 26 of 28 patients (92.3%) tested
positive on the first test after exposure. The mean length developed the following symptoms: malaise in 13, dark
urine in 3, pruritus in 2, and food intolerance or nauseaof time from exposure to batch 93F21AB11B to the first
positive HCV PCR test result was 37.5 days (range, 7– in 4. Histological analysis of the liver was performed on
3 patients: 2 had acute inflammation of the liver typical71 days; n Å 22; 1 SD Å 19.3). Nine of the 12 patients
who underwent Gammagard therapy but who did not of HCV hepatitis. The third was a patient with chronic
lymphocytic leukemia who died suddenly of unrelatedreceive the implicated batch (93F21AB11B) have all
tested negative for HCV PCR on at least two occasions. causes; postmortem examination showed marked
lymphocytic infiltration of the liver with lymphoid folli-Of the 3 remaining patients, 1 patient was positive by
PCR previously and had chronic hepatitis C infection cle formation. Immunohistochemical staining has shown
the cells to be predominately of T-cell origin (suggestingafter transmission by previous IV Ig product (not Gam-
magard); 1 patient has been tested only once (negative); HCV rather than chronic lymphocytic leukemia as the
cause of the changes). Only 1 of the 12 patients notand data were not available for the third patient. In 21
of the 34 exposed patients (61.8%), sera were available exposed to the implicated batch (93F21AB11B) had any
documented change in liver function test results; thisbefore exposure (in 15 of 21 patients [71.4%] sera were
available from the month immediately before their expo- change was transient after a chest infection treated with
broad-spectrum antibiotics.sure) and they tested for RT-PCR. Only 1 of these patient
was HCV RNA–positive before exposure. He was a pa- The 4 patients exposed to the batch but who had no
findings of HCV viremia or anti-HCV seroconversiontient with common variable immunodeficiency (CVID)
and autoimmune hemolytic anemia who had received did not seem to be significantly different in age, sex,
indication for IV Ig (two CVIDs and two Ig subclassother blood products in the past. Genotyping of 20 iso-
lates from 14 patients have all shown genotype 1a. deficiencies), or dose of the implicated batch.
In summary, of 34 patients in the United KingdomFurther sequence analysis of the NS5 region of the
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Table 2. Summary of Previous Outbreaks of HCV in Patients Undergoing IV Ig Therapy
Country Year Study Product Outbreak HCV PCR Cirrhosis
United Kingdom 1983 Lane,6 Lever et British Blood Products 12/12 IV Ig–treated patients 5/5 positive 3 cases by
al.7 Laboratory, Elstree developed non-A, non-B 1986
hepatitis
United States 1988 Ochs et al.5 Hyland Therapeutics 7/16 IV Ig–treated patients 10/15 positive 2 cases by
Division, California developed non-A, non-B 1986
hepatitis
Sweden 1988 Bjorkander et al.8 Gammonativ, 16/77 treated patients 8/10 positive 3 cases in initial
Kabivitrium developed non-A, non-B report
hepatitis
Scotland 1989 Williams et al.9 Scottish National 4/34 treated patients 3/4 positive Not known
Blood Transfusion developed non-A, non-B
Service hepatitis
Sweden 1986 Weiland et al.10 Gammonative, 4 patients with non-A, non-B Not known 2 cases in initial
Kabivitrium hepatitis report
Sweden 1986 Hammarstrom and Not reported 1 patient with non-A, non-B 1/1 positive 1 in initial report
Smith31 hepatitis
Norway/ 1994 Bjoro et al.12 Gammonativ, 17 HCV-positive by PCR from 17/54 positive 5 cases by
Sweden Kabivitrium 54 patients treated 1982– 1994
1986
United Kingdom 1994 Healey (present Gammagard; Baxter– 28 HCV-positive by PCR from 28/34 positive Not known
study) Hyland 36 patients exposed to
one batch of IV
United States 1994 MMWR17 Gammagard; Baxter– 110 suspected cases of HCV Not known Not known
Hyland infection treated with
Gammagard
followed up since exposure to a contaminated batch by infected individuals who remain seronegative for a
long term.19 Each batch of Gammagard is produced from(93F21AB11B) of Gammagard, 30 developed HCV in-
fection. Twenty-eight were found to be HCV positive a plasma pool (approximately 12,000 L) made from ap-
proximately 15,000 individual donations from severalby PCR, and 2 patients were anti-HCV positive with
abnormal liver function tests. Sequence analysis has thousand donors. The plasma pool then undergoes cryo-
precipitation and alcohol precipitation to produce severalshown almost identical virus isolates from the implicated
batch as well as all 20 isolates tested from the recipients. protein fractions; the g-globulin–containing fraction is
further purified by chromatography. Although the alco-Discussion hol precipitation steps have been shown to denature re-
We have shown that the use of an IV Ig product troviruses, the ability to remove HCV is unproven.20
(Gammagard) made from blood screened for anti-HCV HCV RNA could still be detected by nested PCR in the
antibody was associated with the transmission of acute g-globulin fraction but at a greatly reduced titer com-
hepatitis C from one contaminated batch. No infection pared with that of the starting plasma pool, so that infec-
was found in patients treated with 16 different batches tivity was thought to be unlikely.15 In addition, IV Ig
of the same product in the United Kingdom during the made from infectious plasma using various methods, in-
14 months before withdrawal. Analysis of virus isolates cluding that used to produce Gammagard, had been
from the infected patients has shown the same subtype shown not to transmit HCV to chimpanzees in limited
of the virus, and nucleotide sequence analysis of the NS5 animal tests.21 Whether this outbreak is related to HCV
region of the viral genome shows virtually no variation screening or proves to be restricted to the manufacturing
between any of the isolates. An identical sequence has process (now modified by the addition of solvent or deter-
also been amplified from the implicated batch. Such gent inactivation) is unknown.
findings are consistent with infection from a single donor. Because of the concern for potential HCV transmis-
For breakthrough of HCV infection to have occurred, sion, improvements in the production of IV Ig have been
there must have been both failure of anti-HCV screening introduced, such as the addition of a solvent detergent
to detect donor infection and lack of complete removal step for the inactivation of HCV because this virus is
of infectious HCV by the production method. Anti-HCV sensitive to organic solvents. Further improvements of
screening can fail if plasma is donated after exposure to antibody-based screening would not completely remove
the risk of seronegative but HCV RNA–positive dona-HCV but before seroconversion or if plasma is donated
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tions. The adoption of HCV RNA detection from indi- evidence of such antibodies may be the only indication of
HCV transmission.vidual donations by RT-PCR would be expensive and
difficult to standardize. The readoption of surrogate The transmission of viruses through the use of blood
markers such as abnormal transaminase values may fur- and blood products has been a major medical problem,
ther identify HCV-positive donors who remain negative perhaps most tragically illustrated with the inadvertent
on anti-HCV tests. However, HCV infection is often human immunodeficiency virus infection of hemophili-
found with persistently normal liver function despite acs. However, the problem has not been restricted to
active liver disease.22 One possible option would be intro- human immunodeficiency virus, as clearly shown by the
ducing HCV RNA testing of the finished IV Ig product, current outbreak of hepatitis C that accompanied the use
although interpretation of positive results remains uncer- of screened IV Ig (Gammagard). This emphasizes the
tain with regard to infectivity. importance of regarding Ig preparations with the same
care that is afforded to other blood products. CarefulIn immunocompetent individuals, hepatitis C usually
documentation of batch numbers and regular biochemi-causes chronic infection that may progress to cirrhosis
cal monitoring is recommended for all IV Ig recipients.and hepatocellular carcinoma.23–26 There have been sev-
eral previous outbreaks of non-A, non-B hepatitis associ-
Referencesated with the use of IV Ig (now known to be caused by
HCV).5–8,10,23–26 Many of the patients developed signifi- 1. Chapel HM. Consensus in diagnosis and management of primary
antibody deficiencies. BMJ 1994;308:581–585.cant liver disease (Table 2),8,12,27 and cirrhosis was found
2. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG.in 17 of 61 patients (27.9%). Thus, in this patient group,
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